Table 4.
Peripheral blood Tregs* pre- and post-vaccination
| Patient | Sample | % Treg in CD4+ | Ratio of Teff:Treg** |
|---|---|---|---|
| Breast cancer patients: | |||
|
| |||
| 1 | Pre D131 |
5.3%
3.9% |
12.5:1
17.8:1 |
| 8 | Pre D44 |
2.4% 2.5% |
35.1:1 22.5:1 |
| 12 | Pre D27 |
2.6% 5.1% |
28.9:1 13.1:1 |
| 13 | Pre D41 |
8.2%
6% |
7.5:1
11.5:1 |
| 23 | Pre D70 |
3% 2.3% |
22.3:1
29.3:1 |
| 24 | Pre D71 |
4.2% 5.9% |
13.6:1 10.4:1 |
|
| |||
| Ovarian cancer patients: | |||
|
| |||
| 2 | Pre D71 |
3.3% 4.2% |
21.8:1 16.9:1 |
| 3 | Pre D28 |
4.5% 4.0% |
16.2:1 16.9:1 |
| 5 | Pre D70 |
3.1% 3.7% |
21.6:1 17.7:1 |
| 7 | Pre D76 |
6.2%
4.2% |
9.2:1
14.2:1 |
| 10 | Pre D77 |
6.4%
3.4% |
9.1:1
17.7:1 |
| 11 | Pre D76 |
3.8% 4.4% |
17:1 14:1 |
| 14 | Pre D71 |
5.1%
4.0% |
13.5:1
17.5:1 |
| 19 | Pre D69 |
2.4% 3.1% |
23.3:1 18.3:1 |
*
Tregs (T regulatory cells) defined as CD4+CD25highFoxp3+, percentage of CD4+CD25highFoxp3+ in CD4+ cells.
**
Ratio of Teffs (T effector cells; CD4+CD25−) to Tregs (CD4+CD25highFoxp3+).
Bold font indicates decreases in Treg or increases in Teffs:Treg.